Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03480282 · ClinicalTrials.gov registry record · NA

Discussing Stopping Cancer Screening and Prognosis With Older Adults

A NA study of Cancer Screening, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
NA
Development phase
90
Enrollment target
2
Study locations

NCT03480282: Completed NA study of Cancer Screening, sponsored by Beth Israel Deaconess Medical Center.

NCT03480282 is a NA study of Cancer Screening that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 90 participants, below the 664-participant average among 4 other Cancer Screening trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03480282, a NA study of Cancer Screening, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
NA
Development phase
90 participants
Enrollment target
2
Study locations

Study Summary

Guidelines recommend not screening adults with \<10-year life expectancy for cancer; however, primary care physicians feel uncomfortable talking to older adults about prognosis. The investigators aim to determine whether providing PCPs with scripts on patient prognosis and older adults with information on their prognosis would be useful when recommending stopping cancer screening.

Primary Outcome

Intentions to be screened was measured in a pretest-survey and again within 2 weeks of a PCP visit using the choice/predisposition scale which is measured from 1-15 on a 15 point scale. A score of 1 means that a person does not intend to be screened. A score of 15 means that the person does intend to be screened. A score of 8 means they are unsure. Scores between 2-7 means the person is leaning towards not being screened. A score of 9-14 means that person is leaning towards being screened. We ex

Conditions Studied

Interventions

  • OTHER Prognosis information and Provider Scripts

Study Locations (2)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • BIDMC Affiliated Physicians Group - Boston

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2017-10-03
Est. Completion 2021-10-01
Phase NA

What the finished NCT03480282 record still lists

NCT03480282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 664-participant average among 4 other Cancer Screening trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Cancer Screening appearing as the primary indexed condition, and to 1 intervention - of which Prognosis information and Provider Scripts is the first listed.

NCT03480282 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03480282 about?

NCT03480282 is a clinical study titled "Discussing Stopping Cancer Screening and Prognosis With Older Adults". Guidelines recommend not screening adults with \<10-year life expectancy for cancer; however, primary care physicians feel uncomfortable talking to older adults about prognosis. The investigators aim to determine whether providing PCPs with scripts on patient prognosis and older adults with informat...

What is the current status of trial NCT03480282?

This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2017-10-03. Estimated completion is 2021-10-01.

What conditions does trial NCT03480282 study?

This clinical trial studies the following conditions: Cancer Screening.

What interventions are being tested in trial NCT03480282?

The interventions under investigation include: Prognosis information and Provider Scripts (OTHER).

Who is sponsoring clinical trial NCT03480282?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03480282 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Screening

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03480282, the US trial registry maintained by the National Library of Medicine. NCT03480282 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.